Cannabidiol

Generic Name: Cannabidiol

Brand Names: Epidiolex, Sativex, Epidyolex

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀O_₂

CAS Number: 13956-29-1

Unique Ingredient Identifier: 19GBJ60SN5

Background: Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investig...

Indication: When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications:
...

Associated Conditions: Multiple Sclerosis, Seizures, Severe Pain, Moderate Pain

Associated Therapies: -

Clinical Trials

Cannabidiol in Youth Alcohol Use Disorder

Phase 2

Completed

Conditions: Alcohol Use Disorder

Interventions: Drug: Cannabidiol

First Posted Date: 2022-04-08

Last Posted Date: 2024-07-24

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 44

Registration Number: NCT05317546

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

CBD in Postmenopausal Women With Osteopenia

Phase 1

Terminated

Conditions: Osteopenia

Interventions: Drug: CBD
Other: Placebo

First Posted Date: 2022-04-07

Last Posted Date: 2022-09-23

Lead Sponsor: Canopy Growth Corporation

Target Recruit Count: 2

Registration Number: NCT05317013

Locations: 🇺🇸
NM Clinical Research & Osteoporosis Center, Inc., Albuquerque, New Mexico, United States

Reducing Pain and Opioid Use With CBD

Phase 2

Recruiting

Conditions: Opioid Use Disorder

Interventions: Drug: Placebo
Drug: Cannabidiol

First Posted Date: 2022-03-29

Last Posted Date: 2024-10-01

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 150

Registration Number: NCT05299944

Locations: 🇺🇸
University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸
University of Colorado Denver, Aurora, Colorado, United States

Cannabidiol in the Treatment of Opioid Use Disorder

Phase 1

Completed

Conditions: Opioid Use Disorder

Interventions: Drug: Cannabidiol 200mg
Drug: Epidiolex
Drug: Cannabidiol 400mg
Drug: Placebo

First Posted Date: 2022-03-08

Last Posted Date: 2024-01-23

Lead Sponsor: Yasmin Hurd

Target Recruit Count: 200

Registration Number: NCT05269706

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Cannabidiol Effects on Cardiovascular System and Exercise Responses

Early Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Cannabidiol

First Posted Date: 2022-02-09

Last Posted Date: 2024-03-27

Lead Sponsor: Castleton University

Registration Number: NCT05232123

Locations: 🇺🇸
Castleton University, Jeffords Science Building, Castleton, Vermont, United States

Topical CBD for Musculoskeletal Pain

Phase 2

Withdrawn

Conditions: Musculoskeletal Pain

Interventions: Drug: CBD
Other: Control

First Posted Date: 2021-12-28

Last Posted Date: 2024-02-28

Lead Sponsor: University of Virginia

Registration Number: NCT05170451

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Reducing the Harmful Effects of Cannabis Use: Finding the Optimal CBD:THC Ratio

Not Applicable

Completed

Conditions: Cannabis Use

Interventions: Drug: THC
Drug: Cannabidiol

First Posted Date: 2021-12-27

Last Posted Date: 2021-12-27

Lead Sponsor: King's College London

Target Recruit Count: 46

Registration Number: NCT05170217

Locations: 🇬🇧
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom

Evaluation of Oral THC and CBD in Men and Women

Phase 1

Not yet recruiting

Conditions: Drug Abuse
Intoxication by Drug
Impairment

Interventions: Drug: Placebo
Drug: THC
Drug: CBD
Drug: THC + CBD

First Posted Date: 2021-10-05

Last Posted Date: 2024-12-10

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 22

Registration Number: NCT05067387

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

Cannabidiol for Reduction of Brain Neuroinflammation

Phase 2

Recruiting

Conditions: Depressive Symptoms
Back Pain

Interventions: Other: Placebo
Drug: CBD

First Posted Date: 2021-10-04

Last Posted Date: 2024-02-07

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 80

Registration Number: NCT05066308

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Phase 4

Active, not recruiting

Conditions: Lennox Gastaut Syndrome
Dravet Syndrome
Tuberous Sclerosis Complex

Interventions: Drug: Cannabidiol

First Posted Date: 2021-09-16

Last Posted Date: 2024-12-16

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 154

Registration Number: NCT05044819

Locations: 🇺🇸
Clinical Trial Site, Winchester, Virginia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy